bloomberg article

Avexa Says HIV Medicine Fights Virus in 48-Week Patient Study

By Simeon Bennett

March 12 (Bloomberg) -- Avexa Ltd., which is developing a medicine to treat drug-resistant HIV, said a study showed its experimental treatment reduced the virus to undetectable levels in 90 percent of patients after 48 weeks.

Avexa's drug, called apricitabine or ATC, also helped increase patients' CD4 cells, the infection-fighting cells that are destroyed by HIV, the Melbourne-based company said in a statement today. No resistance to the drug has been identified and no serious side effects were observed, the company said.

Avexa shares rose 1 cent, or 2.4 percent, to 42 cents on the Australian Stock Exchange at 12:48 p.m. Sydney time.